Atara Biotherapeutics , Inc. (Nasdaq: ATRA ), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases "Atara made significant progress in 2020 and is well-positioned for a strong 2021," said...
Seeing a turn in cancer genetics incorporated... looks juicy. Triple bottom structure with a recent falling wedge breakout on the overall expanding downward channel. Each time on the turning point of this major multi year support we saw major impulsive moves shortly after. Given that the price in time now is at a much lower discount compared to history. I think...
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol. A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also...
Consolidating above VPOC with fib targets above.
It looks like this stock is ready to spike. On 6/10/2020, NK said its NK cells appear to be resistant even to acute hypoxia and are capable of maintaining tumor killing activity in conditions comparable with a suppressive tumor microenvironment. Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information...
AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday. DD: OGEN has *1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15...
NASDAQ:CLVS 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks FDA date of approval - 15.05.2020 Our Strategy with this Stock : This company provides prostate cancer therapy . And as you can see there is huge previous spikeability in the company regarding their previous drug in their pipelines . It's going to be the first targeted therapy...
Is $MBRX- The Best Biotech with the most upside Potential Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the...
#SeattleGenetics is doing several impressive studies which helped stock price moved up.They stayed strong during the crash. It is doing well so far but it may stall for a while because of the coming resistances.
Technicals analysis WEEKLY Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull) 50SMA is now crossing above the 200SMA. (Bull) OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June. Headlines /...
"Microsoft and Adaptive Biotechnologies announce partnership using AI to decode immune system; diagnose, treat disease" They also have a partnership with Genentech (January 2019) ADPT - Adaptive Biotechnology IPO: June 27th 2019 - open @$39 (above current price) Vision: We aim to improve people’s lives by translating the scale and precision of their...
Hi Guys Following my ideas redarding #cellectis. A promising french biotech company that already celebrates hugh success with "their" ucart19 against leukemia. Check out my thoughts and join the conversatioin. TA: - Double bottom which is normally an indicator for a reversal. - higher high and higher low - Oversold Stoch RSI (4hr) - Rising...
We've seen a major sell off but the floor held above a penny -- a good sign considering the amount of flippers and pump victims from ihub. With the conference this week vivid should gain some much needed exposure and perhaps make another substantial leap back in the green.
Set up a longer term chart with some future potential targets. You can see the chart supports fundamentals given recent company news, so this doesn't appear to be a pump or flash in the pan (as we saw two months ago). Looking very bullish in the near term and beyond.
BLRX BL-8040 Overview BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. Solid Tumors: In January 2016, BioLineRx entered into a collaboration with MSD, known as ...
Did some fundamental DD and i see many upside potential in this stock over the long term. Why is this stock so cheap to begin with? The stock is undervalued and should be at 8-10 dollar range atm. Now is a good time to buy. Every negative thing that can happen is already baked in the stock price. Not much to short anymore. When things don't work out, i don't see...
CRSP Gains, gains, more gains. Looking good so far this year. Gene editing seeking to cure diseases and cancer. Don't sleep on this one. Hitting some all time highs right now so wait for a moment to get down to the $22's and $21's and watch for a good return in the future.